Back to News
Market Impact: 0.25
Genmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal Cancer
Source: Nasdaq
Healthcare & Biotech
Genmab reported updated Phase 2 data showing that petosemtamab combined with standard chemotherapy continued to demonstrate encouraging response rates in patients with metastatic colorectal cancer. The findings were presented at the ESMO Congress; the article provides no numerical response rates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GMAB0.55
More News
- Genmab shares jump 13% on colorectal cancer drug trial results
- Genmab's Encouraging Oncology Data Boosts Investor Optimism
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma